Search - tctmd.com

Displaying 61 - 80 of 81

Sort: Relevancy | Date

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Shelley Wood

June 21, 2018

News Conference News The Structural Heart Disease Summit 2018

Nearly 25% of AVR Patients Experience Anxiety or Depression in First Year

Michael O'Riordan

June 21, 2018

News Daily News

One-Third of TAVR and SAVR Patients Are Depressed, Upping Mortality Risk

L.A. McKeown

January 18, 2018

News Daily News

The Biggest News of 2017: TCTMD’s Top 10

Shelley Wood

January 01, 2018

News Daily News

Complications Spiked, Then Fell, After Initial Introduction of Watchman LAA Closure Device

Todd Neale

October 12, 2017

News Conference News PCR London Valves 2017

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

Shelley Wood

September 24, 2017

News Conference News TVT 2017

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Michael O'Riordan

June 20, 2017

News Features

Valve, Heal Thyself: Pioneers Seek Tissue-Engineered Fix for Faulty, Failing Cardiac Parts

Caitlin E. Cox

June 14, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Daily News

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

Todd Neale

May 17, 2017

News Conference News ACC 2017

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

Shelley Wood

March 23, 2017

Presentation TCT 2016

TMVR Clinical Trial Design: Early Insights from Industry

Presenter: Charles J. Davidson, Nicole Ibrahim, Dan Mans

October 30, 2016

Presentation TCT 2016

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

Presenter: Charles J. Davidson, Nicole Ibrahim, Paul Sorajja

October 30, 2016

Presentation TCT 2016

FDA Perspectives

Presenter: Charles J. Davidson, Nicole Ibrahim, John C Laschinger

October 30, 2016

News Daily News

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

L.A. McKeown

August 24, 2016

News Daily News

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Yael L. Maxwell

August 18, 2016

News Conference News TVT 2016

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Michael O'Riordan

June 16, 2016

News Daily News

Los Expertos Eligen los Avances Más Importantes de 2011

Jason Kahn

March 08, 2012

News Daily News

Estudio se Centra en la Inflamación Sistémica tras la TAVR

Caitlin E. Cox

March 07, 2012

News Daily News

Las Sociedades Recomiendan los Requisitos para el Programa TAVR

L.A. McKeown

March 06, 2012

Advertisement

Data or Money: What’s Holding Back Cerebral Embolic Protection in TAVR?

Nearly 25% of AVR Patients Experience Anxiety or Depression in First Year

One-Third of TAVR and SAVR Patients Are Depressed, Upping Mortality Risk

The Biggest News of 2017: TCTMD’s Top 10

Complications Spiked, Then Fell, After Initial Introduction of Watchman LAA Closure Device

TAVR Takeover? Experts Debate Timing of Surgery’s Ousting in Aortic Stenosis

Merits of Minimalist TAVR: Patient Satisfaction and a Better Bottom Line

Valve, Heal Thyself: Pioneers Seek Tissue-Engineered Fix for Faulty, Failing Cardiac Parts

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

‘Reassuring’ Results for Watchman LAA Closure Device Seen in EWOLUTION Registry

My Takeaways From ACC 2017: Even With a Sea Change, the Tide Takes Its Time

TMVR Clinical Trial Design: Early Insights from Industry

TMVR Clinical Trial Design: Similarities and Differences -TAVR and Transcatheter Mitral Therapy Clinical Trials

FDA Perspectives

Survival Better, No ‘Risk Creep’ for TAVR vs Surgery in Lower-Risk Patients

FDA Approves Sapien XT and Sapien 3 for Intermediate-Risk Patients

Minimalist Transfemoral TAVR Reduces Costs Without Adversely Affecting Clinical Outcomes

Los Expertos Eligen los Avances Más Importantes de 2011

Estudio se Centra en la Inflamación Sistémica tras la TAVR

Las Sociedades Recomiendan los Requisitos para el Programa TAVR

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content